Resilient Growth Amidst Funding Fluctuations: How Syngene’s Strategic Vision Outperformed the Market
Syngene Expects Biz to Pick Up by H2 on Funding Revival
Biosecurity threats and business as usual
Three Indian CDMOs ready to seize the BIOSECURE Act opportunity
Indian pharma implements sustainable practices to prevent plastic use & switch to renewable energy sources
Home and US CAPEX places India on brink of bioCDMO breakthrough
Syngene expects benefits from big pharma’s China-plus-one strategy
Elevating Biomanufacturing Efficiency with N-1 Perfusion Technology
Global CDMO Trends: the 2024 outsourcing forecast
ADCs present compelling opportunity to deliver crucial drugs, particularly for oncology medications
